other material
confidence high
sentiment positive
materiality 0.60
Estrella Immunopharma receives Buy rating from D. Boral Capital with $16 price target
Estrella Immunopharma, Inc.
- D. Boral Capital initiates coverage on Estrella (ESLA) with a Buy rating and 12-month price target of $16.00 per share.
- Lead candidate EB103, a CD19/CD22-targeted ARTEMIS® T-cell therapy, is in Phase I/II trials for B-cell Non-Hodgkin's Lymphoma.
- D. Boral Capital's valuation model assumes 30% probability of success and a 30% discount rate.
- D. Boral Capital will also provide investment banking services, creating a potential conflict of interest.